Abstract: A Ras protein degradation inducing molecule that can induce degradation of Ras proteins, and a pharmaceutical composition that contains this Ras protein degradation inducing molecule are provided. The Ras protein degradation inducing molecule is a conjugate of a Ras protein affinity molecule which has affinity to Ras proteins, and a proteolysis-inducing tag which has affinity to protease and does not inhibit proteolysis of proteins by the protease.

Abstract: A hydrogen storage cartridge small and lightweight allows storage and discharge of hydrogen at low pressure and normal temperature. It also can effectively absorb the volume expansion accompanying atomization of a hydrogen storage alloy that occurs due to repeated storage and discharge of hydrogen, and therefore a hydrogen storage cartridge (A) is provided in which deformation due to repeated use, and in particular irregular deformation, extremely unlikely, also it can effectively avoid hydrogen storage irregularities of the hydrogen storage alloy. The hydrogen storage cartridge (A) is used for storage of hydrogen contained in biomass thermal decomposition gas, wherein the material of the hydrogen storage cartridge (A) is pure titanium, and the hydrogen storage cartridge (A) includes in the interior space (1), as a hydrogen storage alloy, at least one hydrogen storage alloy selected from the group comprising lanthanum mischmetal/nickel, titanium/iron, calcium/nickel, and lanthanum/nickel.

Abstract: A molecular kinetics evaluation method is provided which involves: a step for dosing a human or non-human animal with a proteolysis-inducing molecule, which is a conjugate of a proteolysis induction tag, i.e., a molecule which has affinity for protease and which does not inhibit proteolysis by protease, and a specific protein affinity molecule having affinity to a specific protein, and inducing proteolysis of the specific protein in vivo in the human or non-human animal; and a step for evaluating the molecular kinetics of the specific protein affinity molecules or the proteolysis-inducing molecules by detecting proteolysis of the specific proteins in a sample which is at least part of the human or non-human animal.

Abstract: A switched reluctance motor system includes a switched reluctance motor, a rotor including a plurality of salient poles, a stator including a plurality of salient poles, coils of three phases wound around the salient poles of the stator, and an electronic control unit. The electronic control unit is configured to drive the switched reluctance motor in a pole configuration pattern of NSNSNS in which the salient poles of the stator that have different polarities are alternately arranged. The electronic control unit is configured to perform current waveform control when an excitation sound frequency of a given order coincides with a resonance frequency of the switched reluctance motor.

Abstract: A p53 degradation inducing molecule which can induce degradation of p53 proteins or p53 composites, and a pharmaceutical composition containing said p53 degradation inducing molecule are provided. This p53 degradation inducing molecule is a conjugate of a p53 affinity molecule which has affinity for p53 proteins or p53 composites, and a proteolysis induction tag which has affinity for protease and which does not inhibit proteolysis of proteins by protease.

Abstract: The present invention relates to a compound represented by the general formula (A), a base generator comprising the compound, a base-reactive composition which comprises the base generator and a base-reactive compound, as well as a method for generating a base, etc.

Abstract: Provided is the positive electrode active material for a potassium ion battery according to the embodiment comprises a compound represented by Formula (1), in which M represents at least one element selected from the group consisting of V, Fe, Co, Ni, and Mn, and x represents a number from 0 to 1; and is a positive electrode for a potassium ion battery comprising the positive electrode active material for a potassium ion battery according to the embodiment, or a potassium ion battery comprising the positive electrode for a potassium ion battery.

Abstract: A method for recovering hydrogen which is capable of efficiently recovering high concentration hydrogen gas by adsorbing and removing hydrocarbon gas such as carbon dioxide from biomass pyrolysis gas under a relatively low pressure, and also capable of storing the recovered high concentration hydrogen gas, preferably, in a cartridge type container that can be used as is as a hydrogen storing container for an apparatus equipped with a fuel cell. The method includes a first purifying stare of purifying biomass pyrolysis gas and a second purifying stage of purifying the obtained purified gas under a pressure equal to or less than the pressure in the first purifying stage to recover gas that contains hydrogen, and further includes a hydrogen storing stage of feeding the gas containing hydrogen recovered in the second purifying stage into the container filled with a hydrogen storage alloy and storing high purity hydrogen.

Abstract: Disclosed is a rare-earth complex polymer including trivalent rare-earth ions and a phosphine oxide bidentate ligand represented by the formula (1). One phosphine oxide bidentate ligand is coordinated to the two rare-earth ions, and crosslinks the same.

Abstract: A positive electrode active material for a magnesium secondary battery, and a positive electrode for a magnesium secondary battery and a magnesium secondary battery in which the positive electrode active material is used are provided. The positive electrode active material consists of a magnesium composite oxide which is represented by Formula (1): MgxM1yM2zO2 and which has a rock salt-type crystal structure of space group Fm-3m. In Formula (1), M1 is Ni, Co, or Mn, M2 is different from M1 and is at least one element selected from the group consisting of Ni, Co, Mn, Ti, V, Cr, Fe, Cu, Nb, W, Mo, and Ru, 0<x?1, 0<y<2, 0<z<1; and 1.5?x+y+z?2.0.

Abstract: Provided is a novel lithium complex oxide containing molybdenum. A complex oxide represented by the following compositional formula: LixMyMozO wherein M is one or two or more selected from the group consisting of Mn, Ru, Sn, Mg, Al, Ti, V, Cr, Fe, Co, Ni, Cu, and Zn; x is in the range of 0.60 to 0.75; y is in the range of 0.15 to 0.25; and z is in the range of 0.075 to 0.20.

Abstract: Provided is a hydrogen recovery method such that highly concentrated hydrogen gas can be obtained efficiently by adsorbing and removing hydrocarbon gas such as carbon dioxide, carbon monoxide, and methane, using a relatively low pressure, from pyrolysis gas obtained by heat treating biomass. The present invention is the method for recovering hydrogen from pyrolysis gas obtained by heat treating biomass, characterized by including: a first purifying step of adsorbing and removing gas that mainly includes carbon dioxide under pressure from the pyrolysis gas to purify the pyrolysis gas; and a second purifying step of further adsorbing and removing gas that includes carbon dioxide under pressure from purified gas obtained by the first purifying step at a pressure lower than the pressure in the first purifying step to purify the purified gas in order to recover hydrogen from the purified gas.

Abstract: A switched reluctance motor system includes a switched reluctance motor, a rotor including a plurality of salient poles, a stator including a plurality of salient poles, coils of three phases wound around the salient poles of the stator, and an electronic control unit. The electronic control unit is configured to drive the switched reluctance motor in a pole configuration pattern of NSNSNS in which the salient poles of the stator that have different polarities are alternately arranged. The electronic control unit is configured to perform current waveform control when an excitation sound frequency of a given order coincides with a resonance frequency of the switched reluctance motor.

Abstract: The present invention relates to a triblock copolymer having a polyethylene glycol-poly(D,L-lactide)-polyethylene glycol skeleton.

Abstract: A positive electrode active material for a magnesium secondary battery, and a positive electrode for a magnesium secondary battery and a magnesium secondary battery in which the positive electrode active material is used are provided. The positive electrode active material consists of a magnesium composite oxide which is represented by Formula (1): MgxM1yM2zO2 and which has a rock salt-type crystal structure of space group Fm-3m. In Formula (1), M1 is Ni, Co, or Mn, M2 is different from M1 and is at least one element selected from the group consisting of Ni, Co, Mn, Ti, V, Cr, Fe, Cu, Nb, W, Mo, and Ru, 0<x?1, 0<y<2, 0<z<1; and 1.5<x+y+z?2.0.

Abstract: An active ray-curable composition characterized by containing a photobase generator, a double bond-containing compound, and a ?-dicarbonyl compound.

Abstract: Provided are: a protein degradation inducing tag which is a molecule that has affinity with proteases and does not inhibit degradation of a protein by proteases; a protein degradation inducing molecule that is a conjugate of at least one protein degradation inducing tag and at least one protein binding molecule that binds to a protein; and a usage of those.

Abstract: In a control device for a switched reluctance motor, a voltage drop control is executed in which a voltage dropped to be lower than a voltage applied in a case where the switched reluctance motor is driven in a high-load region is applied to the switched reluctance motor, in a case where the switched reluctance motor is driven in a low-load region. The low-load region is a lower load region than the high-load region.

Abstract: The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.

Abstract: A nanogel comprising a self-organizing peptide, a chitosan, and polyethylene glycol.